Ironwood Pharmaceuticals

At the Wells Fargo conference, Ironwood highlighted that a realignment of the LINZESS pricing strategy increased net revenues by $300–350 million and lifts the annual LINZESS guidance to over $1 billion. The company paid off a $200 million convertible note, reduced leverage to under 1.0x EBITDA, and says it is well-positioned financially to continue developing Apraglutid. The FDA is requiring a confirmatory study after an identified dosing issue for Apraglutid; Ironwood is targeting an NDA filing in 2029 and emphasizes the large, underexploited market potential in SBS-IF. » More on de.investing.com

Ironwood reiterated guidance for fiscal 2026 adjusted EBITDA of at least $300 million, citing eased LINZESS headwinds, higher U.S. LINZESS sales and disciplined expense control to support cash flow and debt reduction. Citizens analyst Jason Butler maintained an Outperform rating and raised the price target from $8 to $10 after fourth-quarter results met guidance and the company reaffirmed its 2026 outlook. Ironwood is prioritizing maximizing LINZESS revenue while advancing apraglutide, with initiation of STARS-2 confirmatory Phase 3 sites expected in Q2. » More on finance.yahoo.com

Ironwood Pharmaceuticals forecasts 2026 U.S. net sales for LINZESS of more than $1.1 billion and is targeting adjusted EBITDA of over $300 million. A confirmatory Phase III study for Apraglutid (STARS-2) is planned to start in the second quarter; a regulatory submission is scheduled for late 2029. The company aims to repay $200 million in convertible notes by June and reduce total debt to around $300 million by year-end. Strategically, the focus is on using LINZESS cash flows to fund Apraglutid development, pay down debt and pursue potential partnerships outside the U.S. » More on de.investing.com